MODULATION OF 2'5' OLIGOADENYLATE SYNTHETASE (2,5A)ACTIVITY AND INTERFERON (IFN) BINDING IN PATIENTS (PTS) WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) UNDERGOING IFN THERAPY

被引：0
|
作者：
ROSENBLUM, MG [1 ]
MAXWELL, BL [1 ]
TALPAZ, M [1 ]
GUTTERMAN, JU [1 ]
机构：
[1] UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,HOUSTON,TX 77030
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1984年 / 25卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：230 / 230
页数：1
相关论文
共 50 条
  • [41] IFN-DEPENDENT AND IFN-INDEPENDENT MODULATION OF 2-5A SYNTHETASE-ACTIVITY IN HUMAN HEP G-2 CELLS
    WHYZMUZIS, C
    CHANG, CC
    HADMAN, M
    WU, JM
    FEDERATION PROCEEDINGS, 1987, 46 (06) : 2279 - 2279
  • [42] Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)
    Ghanem, Hady
    Kantarjian, Hagop M.
    Champlin, Richard E.
    Katragadda, Lakshmikanth
    Rondon, Gabriela
    Jabbour, Elias J.
    Quintas-Cardama, Alfonso
    Pierce, Sherry A.
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [43] Mobilization at blood progenitor cells (BPC) in patients with chronic myelogenous leukemia (CML) receiving alfa-interferon (IFN) using RHG-CSF
    Carreras, E
    Mazzara, R
    Sole, F
    Sierra, J
    Rovira, M
    UrbanoIspizua, A
    Merino, A
    Colomer, D
    Feliz, P
    Monfort, N
    Marin, P
    Montserrat, E
    Rozman, C
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 307 - 307
  • [44] In vivo interferon system assessed by 2′-5′ oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin
    Shindo, Michiko
    Hamada, Kazushige
    Morikawa, Teruhisa
    Harano, Yuichi
    Nakajima, Tomoaki
    Okuno, Tadao
    HEPATOLOGY RESEARCH, 2008, 38 (12) : 1213 - 1220
  • [45] A phase II study to assess efficacy and safety of interferon α 2b (IFN) in combination with oral cytarabine ocfosfate (YNK01) in patients with chronic myelogenous leukemia (CML).
    Guilhot, F
    Maloisel, F
    Guyotat, D
    Ifrah, N
    Michallet, M
    Reiffers, J
    Tertian, G
    Blanc, M
    Guerci, A
    Bauduer, F
    Brière, J
    Abgrall, JF
    Dascalescu, C
    Rochant, H
    Solary, E
    Bauters, F
    Bouabdallah, R
    Vilque, JP
    Delain, M
    Harousseau, JL
    Rousselot, P
    Morice, P
    Attal, M
    Guilhot, J
    Chastang, C
    BLOOD, 1998, 92 (10) : 627A - 627A
  • [46] IRF1/IRF2 ratio predicts response to interferon (IFN) therapy in chronic myeloid leukemia, chronic phase (CML-CP).
    Venugopal, P
    Perambekam, S
    Li, B
    Andrews, C
    Devemy, E
    Preisler, HD
    BLOOD, 1998, 92 (10) : 255A - 255A
  • [47] SERUM 2',5'-OLIGOADENYLATE SYNTHETASE-ACTIVITY DURING INTERFERON TREATMENT OF CHRONIC HEPATITIS-B
    SHINDO, M
    OKUNO, T
    MATSUMOTO, M
    TAKEDA, M
    TAKINO, T
    SOKAWA, J
    IWATA, A
    SOKAWA, Y
    HEPATOLOGY, 1988, 8 (02) : 366 - 370
  • [48] INCREASED IFN-ALPHA-INDUCED SENSITIVITY BUT REDUCED REACTIVITY OF 2',5'-OLIGOADENYLATE SYNTHETASE (2,5AS) IN TRISOMY-21 BLOOD-LYMPHOCYTES
    GERDES, AM
    HORDER, M
    BONNEVIENIELSEN, V
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1993, 93 (01): : 93 - 96
  • [49] Prase I study of pegylated-interferon α-2A (PEGASYS™) in patients with chronic myelogenous leukemia (CML).
    Talpaz, M
    O'Brien, S
    Cortes, J
    Giles, F
    Rittweger, K
    Hooftman, L
    Rakhit, A
    Kantarjian, H
    BLOOD, 1999, 94 (10) : 530A - 530A
  • [50] Hepatitis C virus NS5A protein interacts with 2′,5′-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner
    Taguchi, T
    Nagano-Fujii, M
    Akutsu, M
    Kadoya, H
    Ohgimoto, S
    Ishido, S
    Hotta, H
    JOURNAL OF GENERAL VIROLOGY, 2004, 85 : 959 - 969
12345